

James Koropatnick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/547824/publications.pdf>

Version: 2024-02-01

82
papers

3,661
citations

182225

30
h-index

156644

58
g-index

84
all docs

84
docs citations

84
times ranked

6544
citing authors

#	ARTICLE	IF	CITATIONS
1	TdIF1-LSD1 Axis Regulates Epithelial-Mesenchymal Transition and Metastasis via Histone Demethylation of E-Cadherin Promoter in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 250.	1.8	8
2	DIY: Visualizing the immune landscape of tumors using transcriptome and methylome data. <i>Methods in Enzymology</i> , 2020, 636, 49-76.	0.4	1
3	miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 951-967.	2.0	36
4	CD5 blockade enhances ex vivo CD8 ⁺ T cell activation and tumour cell cytotoxicity. <i>European Journal of Immunology</i> , 2020, 50, 695-704.	1.6	21
5	Reduced CD5 on CD8+ T Cells in Tumors but Not Lymphoid Organs Is Associated With Increased Activation and Effector Function. <i>Frontiers in Immunology</i> , 2020, 11, 584937.	2.2	4
6	miR-149-3p reverses CD8 ⁺ T-cell exhaustion by reducing inhibitory receptors and promoting cytokine secretion in breast cancer cells. <i>Open Biology</i> , 2019, 9, 190061.	1.5	43
7	Synergistic Antiproliferative Activity of the RAD51 Inhibitor IBR2 with Inhibitors of Receptor Tyrosine Kinases and Microtubule Protein. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 364, 46-54.	1.3	9
8	TdIF1: a putative oncogene in NSCLC tumor progression. <i>Signal Transduction and Targeted Therapy</i> , 2018, 3, 28.	7.1	12
9	Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy. <i>Oncotarget</i> , 2018, 7, e1498439.	2.1	124
10	Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines. <i>PLoS ONE</i> , 2018, 13, e0191766.	1.1	36
11	TTI-621 (SIRP α Fc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. <i>Clinical Cancer Research</i> , 2017, 23, 1068-1079.	3.2	216
12	Voluntary running exercise protects against sepsis-induced early inflammatory and pro-coagulant responses in aged mice. <i>Critical Care</i> , 2017, 21, 210.	2.5	26
13	From Solo in the Silo to Strategic Training Programs. <i>CBE Life Sciences Education</i> , 2016, 15, 1e1.	1.1	3
14	Evaluation of 6-([¹⁸ F] fluoroacetamido)-1-hexanoic-anilide (18F-FAHA) as imaging probe in tumor xenograft mice model. , 2016, , .		1
15	Synergistic Cytotoxicity against Human Tumor Cell Lines by Oncolytic Adenovirus dl1520 (ONYX-015) and Melphalan. <i>Tumori</i> , 2016, 102, 31-39.	0.6	4
16	Non-Covalently Functionalized of Single-Walled Carbon Nanotubes by DSPE-PEG-PEI for siRNA Delivery. <i>Methods in Molecular Biology</i> , 2016, 1364, 151-163.	0.4	11
17	Abstract 3718: Sensitization of human tumor cells to chemotherapy drugs by antisense downregulation of RAD51: Targeting DNA repair to induce synthetic lethality. , 2016, , .		1
18	Evaluating the Effectiveness of Cancer Drug Sensitization & In Vitro and & In Vivo. <i>Journal of Visualized Experiments</i> , 2015, , .	0.2	2

#	ARTICLE	IF	CITATIONS
19	IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells. PLoS ONE, 2015, 10, e0143435.	1.1	27
20	siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumor cells to gemcitabine. Oncotarget, 2015, 6, 22397-22409.	0.8	7
21	Targeted siRNA Silencing of Indoleamine 2, 3-Dioxygenase in Antigen-presenting Cells Using Mannose-conjugated Liposomes. Journal of Immunotherapy, 2014, 37, 123-134.	1.2	33
22	Imaging Tumor Growth Non-invasively Using Expression of MagA or Modified Ferritin Subunits to Augment Intracellular Contrast for Repetitive MRI. Molecular Imaging and Biology, 2014, 16, 63-73.	1.3	23
23	Vaccinia Virus Outperforms a Panel of Other Poxviruses as a Potent Oncolytic Agent for the Control of Head and Neck Squamous Cell Carcinoma Cell Lines. Intervirology, 2014, 57, 17-22.	1.2	8
24	Single-Walled Carbon Nanotubes Noncovalently Functionalized with Lipid Modified Polyethylenimine for siRNA Delivery <i>in Vitro</i> and <i>in Vivo</i> . Bioconjugate Chemistry, 2014, 25, 1744-1751.	1.8	34
25	Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy. Journal of Translational Medicine, 2014, 12, 127.	1.8	9
26	Non-covalently functionalized single-walled carbon nanotube for topical siRNA delivery into melanoma. Biomaterials, 2014, 35, 3435-3442.	5.7	145
27	BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis. Molecular Oncology, 2014, 8, 1429-1440.	2.1	32
28	Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin. Oncotarget, 2014, 5, 2778-2791.	0.8	40
29	Silencing IDO in dendritic cells: A novel approach to enhance cancer immunotherapy in a murine breast cancer model. International Journal of Cancer, 2013, 132, 967-977.	2.3	87
30	Does HPV type affect outcome in oropharyngeal cancer?. Journal of Otolaryngology - Head and Neck Surgery, 2013, 42, 9.	0.9	52
31	Characterization and in vitro cytotoxicity of doxorubicin-loaded \hat{I}^3 -polyglutamic acid-chitosan composite nanoparticles. Biochemical Engineering Journal, 2013, 75, 72-78.	1.8	28
32	High Frequency of Activating PIK3CA Mutations in Human Papillomavirus-Positive Oropharyngeal Cancer; Mutations in Human PIK3CA in HPV+ Oropharyngeal Squamous Cell Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2013, 139, 617.	1.2	68
33	Metallothionein-I- and -II-deficient mice display increased susceptibility to cadmium-induced fetal growth restriction. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E727-E735.	1.8	23
34	Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined Complementary Lethality. Molecular Therapy - Nucleic Acids, 2013, 2, e78.	2.3	15
35	Abstract 3314: Sensitization of human tumor cells to chemotherapy drugs by antisense downregulation of BRCA2 and thymidylate synthase (TS): Induction of synthetic lethality by targeting DNA repair.. , 2013, , .		1
36	Frequent Mutations in TP53 and CDKN2A Found by Next-Generation Sequencing of Head and Neck Cancer Cell Lines. JAMA Otolaryngology, 2012, 138, 732.	1.5	44

#	ARTICLE	IF	CITATIONS
37	A Pilot Study Comparing HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas by Whole Exome Sequencing. <i>ISRN Oncology</i> , 2012, 2012, 1-9.	2.1	31
38	Imaging of Homeostatic, Neoplastic, and Injured Tissues by HA-Based Probes. <i>Biomacromolecules</i> , 2012, 13, 12-22.	2.6	15
39	Detection of circulating tumor cells in advanced head and neck cancer using the cellsearch system. <i>Head and Neck</i> , 2012, 34, 1440-1444.	0.9	103
40	Antisense Technology: From Unique Laboratory Tool to Novel Anticancer Treatments. , 2012, , 145-189.		2
41	Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?. <i>Journal of Translational Medicine</i> , 2011, 9, 25.	1.8	20
42	Flavonoid Fractions from Cranberry Extract Inhibit Growth of Human Tumor Cell Lines. <i>ACS Symposium Series</i> , 2010, , 197-211.	0.5	2
43	Metallothionein and Metal Homeostasis. , 2010, , 143-166.		2
44	Enhancement of cytotoxicity of natural product drugs against multidrug resistant variant cell lines of human head and neck squamous cell carcinoma and breast carcinoma by tesmilifene. <i>Cancer Letters</i> , 2009, 274, 279-289.	3.2	17
45	Expression of functional metallothionein isoforms in papillary thyroid cancer. <i>Molecular and Cellular Endocrinology</i> , 2009, 302, 92-98.	1.6	20
46	Pharmacokinetics and Pharmacodynamics of Hyaluronan Infused into Healthy Human Volunteers. <i>The Open Drug Metabolism Journal</i> , 2009, 3, 43-55.	0.5	16
47	Exosomes as a tumor immune escape mechanism: possible therapeutic implications. <i>Journal of Translational Medicine</i> , 2008, 6, 37.	1.8	96
48	ODN 491, a Novel Antisense Oligodeoxynucleotide That Targets Thymidylate Synthase, Exerts Cell-Specific Effects in Human Tumor Cell Lines. <i>DNA and Cell Biology</i> , 2008, 27, 229-240.	0.9	6
49	The Hyaluronan Receptors CD44 and Rhamm (CD168) Form Complexes with ERK1,2 That Sustain High Basal Motility in Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2007, 282, 16667-16680.	1.6	228
50	Mouse Monocytes (RAW CELLS) and the Handling of Cysteine and Homocysteine S-Conjugates of Inorganic Mercury and Methylmercury. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2007, 70, 799-809.	1.1	4
51	Combination Silencer RNA (siRNA) Targeting Bcl-2 Antagonizes siRNA against Thymidylate Synthase in Human Tumor Cell Lines. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 123-132.	1.3	9
52	Tangeretin and nobiletin induce G1 cell cycle arrest but not apoptosis in human breast and colon cancer cells. <i>Cancer Letters</i> , 2007, 251, 168-178.	3.2	200
53	Induction of functional MT1 and MT2 isoforms by calcium in anaplastic thyroid carcinoma cells. <i>FEBS Letters</i> , 2007, 581, 2465-2472.	1.3	15
54	Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1423-1433.	1.9	24

#	ARTICLE	IF	CITATIONS
55	In Vivo Inhibition of Growth of Human Tumor Lines by Flavonoid Fractions From Cranberry Extract. <i>Nutrition and Cancer</i> , 2006, 56, 86-94.	0.9	75
56	Reinstalling Antitumor Immunity by Inhibiting Tumor-Derived Immunosuppressive Molecule IDO through RNA Interference. <i>Journal of Immunology</i> , 2006, 177, 5639-5646.	0.4	97
57	Antisense Targeting of Thymidylate Synthase (TS) mRNA Increases TS Gene Transcription and TS Protein: Effects on Human Tumor Cell Sensitivity to TS Enzyme-Inhibiting Drugs. <i>Gene Expression</i> , 2006, 13, 227-239.	0.5	9
58	Use of the Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody h-R3 in Combination With Radiotherapy in the Treatment of Locally Advanced Head and Neck Cancer Patients. <i>Journal of Clinical Oncology</i> , 2004, 22, 1646-1654.	0.8	261
59	Metallothionein Mediates the Level and Activity of Nuclear Factor κ B in Murine Fibroblasts. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 310, 589-598.	1.3	53
60	Toxicology of antisense therapeutics. <i>Toxicology and Applied Pharmacology</i> , 2004, 201, 66-83.	1.3	154
61	Signaling events for metallothionein induction. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2003, 533, 211-226.	0.4	334
62	A sensitive time-resolved fluorescent immunoassay for metallothionein protein. <i>Journal of Immunological Methods</i> , 2003, 272, 247-256.	0.6	38
63	Reduction of copper and metallothionein in toxic milk mice by tetrathiomolybdate, but not deferiprone. <i>Journal of Inorganic Biochemistry</i> , 2002, 88, 213-222.	1.5	19
64	The Means to an End of Tumor Cell Resistance to Chemotherapeutic Drugs Targeting Thymidylate Synthase: Shoot the Messenger. <i>Current Drug Targets</i> , 2002, 3, 297-309.	1.0	25
65	Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cells. <i>British Journal of Pharmacology</i> , 2001, 134, 1437-1446.	2.7	16
66	Roles of vitamin C in radiation-induced DNA damage in presence and absence of copper. <i>Chemico-Biological Interactions</i> , 2001, 137, 75-88.	1.7	53
67	Radiation Exposure Does Not Alter Metallothionein III Isoform Expression in Mouse Brain. <i>Biological Trace Element Research</i> , 2000, 74, 23-30.	1.9	8
68	Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. <i>British Journal of Pharmacology</i> , 1999, 127, 1777-1786.	2.7	36
69	Antisense Nucleic Acids Targeted to the Thymidylate Synthase (TS) mRNA Translation Start Site Stimulate TS Gene Transcription. <i>Experimental Cell Research</i> , 1998, 243, 11-21.	1.2	8
70	Discrimination of Run-On Transcription from Constitutive Genes and Antisense Expression Vectors in the Same Cells. <i>BioTechniques</i> , 1997, 22, 64-66.	0.8	1
71	Metallothionein protects DNA from copper-induced but not iron-induced cleavage in vitro. <i>Chemico-Biological Interactions</i> , 1995, 96, 143-155.	1.7	94
72	Metallothionein protein and mRNA in the <i>toxic milk</i> mouse. <i>Biochemical Journal</i> , 1994, 304, 318-319.	1.7	1

#	ARTICLE	IF	CITATIONS
73	Radioimmunoassay of metallothionein in rabbit, rat, mouse, Chinese hamster, and human cells. <i>Biological Trace Element Research</i> , 1991, 30, 245-256.	1.9	13
74	Induction of metallothionein synthesis by zinc in cadmium pretreated rats. <i>Toxicology</i> , 1990, 63, 273-284.	2.0	45
75	Organ-Specific Metallothionein Induction in Mice by X Irradiation. <i>Radiation Research</i> , 1989, 119, 356.	0.7	51
76	Exposure to different forms of cadmium in mice: Differences in metallothionein and alpha-fetoprotein mRNA induction in liver and kidney. <i>Journal of Biochemical Toxicology</i> , 1988, 3, 159-172.	0.5	23
77	Differential Toxicity of Cis and Trans Isomers of Dichlorodiammineplatinum. <i>Journal of Biochemical Toxicology</i> , 1988, 3, 223-233.	0.5	21
78	Amplification of Metallothionein-1 Genes in Mouse Liver Cells in Situ: Extra Copies Are Transcriptionally Active. <i>Experimental Biology and Medicine</i> , 1988, 188, 287-300.	1.1	6
79	Acute treatment of mice with cadmium salts results in amplification of the metallothionein-1 gene in liver. <i>Nucleic Acids Research</i> , 1985, 13, 5423-5439.	6.5	25
80	Mouse Hepatic metallothionein-1 gene cleavage by micrococcal nuclease is enhanced after induction by cadmium. <i>Nucleic Acids Research</i> , 1983, 11, 3255-3267.	6.5	24
81	Pharmacokinetics of Nucleic-Acid-Based Therapeutics. , 0, , 1061-1086.		1
82	COTI-2, a novel small molecule that is active against multiple human cancer cell lines <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 0, 7, 41363-41379.	0.8	124